Tower Research Capital (TRC)’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,930
| Closed | -$127K | – | 5296 |
|
|
2026
Q1 | $127K | Buy |
5,930
+4,296
| +263% | +$60.5K | ﹤0.01% | 1991 |
|
|
2025
Q4 | $15.2K | Sell |
1,634
-11,518
| -88% | -$96.2K | ﹤0.01% | 3302 |
|
|
2025
Q3 | $92.7K | Buy |
13,152
+7,908
| +151% | +$54.4K | ﹤0.01% | 2047 |
|
|
2025
Q2 | $34.1K | Buy |
5,244
+3,326
| +173% | +$22.9K | ﹤0.01% | 3307 |
|
|
2025
Q1 | $15.2K | Sell |
1,918
-8,739
| -82% | -$94.1K | ﹤0.01% | 3232 |
|
|
2024
Q4 | $135K | Buy |
10,657
+9,603
| +911% | +$134K | ﹤0.01% | 1978 |
|
|
2024
Q3 | $14.7K | Sell |
1,054
-22,595
| -96% | -$322K | ﹤0.01% | 3446 |
|
|
2024
Q2 | $326K | Buy |
23,649
+21,949
| +1,291% | +$321K | 0.01% | 1692 |
|
|
2024
Q1 | $28.1K | Sell |
1,700
-205
| -11% | -$3.07K | ﹤0.01% | 2706 |
|
|
2023
Q4 | $27.8K | Buy |
1,905
+212
| +13% | +$2.57K | ﹤0.01% | 3462 |
|
|
2023
Q3 | $20.8K | Sell |
1,693
-1,478
| -47% | -$19.3K | ﹤0.01% | 3337 |
|
|
2023
Q2 | $37.9K | Sell |
3,171
-3,615
| -53% | -$47.2K | ﹤0.01% | 2818 |
|
|
2023
Q1 | $91K | Buy |
6,786
+4,350
| +179% | +$85K | ﹤0.01% | 1951 |
|
|
2022
Q4 | $53K | Buy |
2,436
+250
| +11% | +$5.13K | ﹤0.01% | 2299 |
|
|
2022
Q3 | $44K | Sell |
2,186
-1,564
| -42% | -$33.3K | ﹤0.01% | 3275 |
|
|
2022
Q2 | $67K | Buy |
3,750
+1,940
| +107% | +$20K | ﹤0.01% | 2616 |
|
|
2022
Q1 | $18K | Buy |
1,810
+763
| +73% | +$10.1K | ﹤0.01% | 3618 |
|
|
2021
Q4 | $17K | Buy |
1,047
+513
| +96% | +$10.5K | ﹤0.01% | 3842 |
|
|
2021
Q3 | $12K | Buy |
534
+524
| +5,240% | +$12.6K | ﹤0.01% | 4139 |
|
|
2021
Q2 | $0 | Buy |
+10
| New | +$209 | ﹤0.01% | 5526 |
|
Other funds holding DAWN
Tower Research Capital (TRC)'s DAWN Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 5,930 shares — an estimated $127K sold.
Tower Research Capital (TRC) first reported a position in DAWN in Q2 2021 and held it in 20 quarters. The position peaked at $326K in Q2 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 5,930 Day One Biopharmaceuticals shares in Q2 2026, an estimated $127K.
- Tower Research Capital (TRC) first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 20 quarters.
- Tower Research Capital (TRC)'s Day One Biopharmaceuticals position peaked at $326K in Q2 2024.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.